Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Event Logistics

- PMLiVE

Rise of generics will curb France’s pharma growth

Generics are set to take a serious bite out of the market as a cash-strapped government pushes for cost controls

- PMLiVE

AZ and Takeda drugs should carry heart failure warning

FDA panel claim diabetes drugs Onglyza and Nesina need label updates

- PMLiVE

Quality in Care Hepatitis C programme open for entry

PMGroup's QiC programme aims to recognise best practice in care for hepatitis C in the UK

- PMLiVE

BMS gives Erbitux rights to Lilly in the US

Firm wants to focus on its burgeoning PD-1 cancer range

- PMLiVE

First generic version of Teva’s Copaxone cleared by FDA

Will be marketed as Glatopa by Momenta and Novartis’ Sandoz subsidiary

- PMLiVE

Pfizer breast cancer drug shines in latest trial

Study with Ibrance stopped early because of its success

France flag

France health reforms draw opposition from doctors

Doctors claim the changes will leave them out of pocket

How to account for different motivations in closed loop marketing

While your CLM technology might be brand new, the communications strategy behind should be tried and tested. In fact one of the earliest exponents of rhetoric, Aristotle, can still inform...

Anthill Agency

- PMLiVE

The CementBloc adds new creative leadership team

Robin Tzannes, Sharon Howard-Butler and Marc Law join the US comms agency

UK’s department of Health deploys information campaign to ensure continued vigilance over Ebola

The threat of Ebola being transmitted within the UK may be low but frontline health workers must remain vigilant nevertheless. This is the message being communicated by the Department of...

M3 (EU)

- PMLiVE

AstraZeneca gains FDA orphan status for new cancer drug

Gains a longer patent life for the investigational lung disease drug

- PMLiVE

Health apps won’t change behaviour, says professor

New op-ed argues that many applications have not been tested or approved by a regulator

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links